A study in The New England Journal of Medicine funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development suggests that letrozole may be more effective at helping women with polycystic ovary syndrome (PCOS) become pregnant than clomiphene.
A study in The New England Journal of Medicine funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development suggests that letrozole may be more effective at helping women with polycystic ovary syndrome (PCOS) become pregnant than clomiphene.
Led by researchers from Penn State College of Medicine, the double-blind, multicenter trial enrolled 750 women aged 18 to 40 with at least 1 patent fallopian tube, a normal uterine cavity and a male partner with a sperm concentration of at least 14 million/mL. The couples had to agree to engage in regular intercourse with the intent of conception. The women were randomized to receive letrozole or clomiphene for up to 5 treatment cycles and had visits to determine ovulation and pregnancy, as well as pregnancy tracking. Modified Rotterdam criteria were used to determine PCOS status.
Women in the letrozole group had more cumulative live births than those in the clomiphene group (103 of 374 [27.5%] vs 72 of 376 [19.1%], P=0.007; rate ratio for live birth, 1.44; 95% confidence interval, 1.10 to 1.87) with no significant differences in overall congenital anomalies. However, there were 4 major congenital anomalies in the letrozole group, while the clomiphene group only had 1 (P = 0.65). Letrozole was also associated with a higher cumulative ovulation rate than clomiphene (834 of 1352 treatment cycles [61.7%] vs 688 of 1425 treatment cycles [48.3%], P<0.001). In addition, no significant difference between the groups was seen in pregnancy loss (49 of 154 pregnancies in the letrozole group [31.8%] and 30 of 103 pregnancies in the clomiphene group [29.1%]) or twin pregnancy (3.4% and 7.4%, respectively). Letrozole was associated with a higher incidence of fatigue and dizziness whereas clomiphene was associated with a higher incidence of hot flushes. The rates of other adverse events were similar in the two groups.
The investigators concluded that when compared to clomiphene, letrozole was associated with a higher rate of live birth and ovulation in infertile women with PCOS.
To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary Ob/Gyn Special Delivery.
Phase 2b safety data for Sildenafil Cream against FSAD reported
August 26th 2024In a recent study published in The Journal of Sexual Medicine, Sildenafil Cream, 3.6% was indicated as safe and well-tolerated for use against female sexual arousal disorder in healthy premenopausal women.
Read More
Study: Pelvic floor dilator reduces pelvic floor muscle injury during vaginal delivery
August 6th 2024A new pilot study published in the International Urogynecology Journal found that Materna Medical’s Prep Device, a pelvic floor dilator, reduced full levator ani muscle avulsion during vaginal delivery in first-time mothers.
Read More
Similar success rates for synthetic and nonsynthetic slings in SUI treatment
July 31st 2024A study found that both synthetic and nonsynthetic slings show similar success rates for treating stress urinary incontinence in women, with synthetic slings demonstrating improved operative outcomes and reduced complications.
Read More
First hysterectomy using miniaturized MIRA Surgical System performed
July 30th 2024Virtual Incision Corporation has announced the successful performance of the first benign hysterectomy using their miniaturized robotic-assisted surgery device, MIRA, in a clinical trial assessing its safety and efficacy.
Read More